Scarica l'app Stockscreener
400.69
0.50%
1.99
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché ALNY Giù?
Forum
Previsione
Precedente Chiudi:
$398.70
Aprire:
$395.99
Volume 24 ore:
408.23K
Relative Volume:
0.32
Capitalizzazione di mercato:
$52.94B
Reddito:
$3.21B
Utile/perdita netta:
$43.57M
Rapporto P/E:
1,666.07
EPS:
0.2405
Flusso di cassa netto:
$221.36M
1 W Prestazione:
+2.19%
1M Prestazione:
-7.72%
6M Prestazione:
+23.29%
1 anno Prestazione:
+64.72%
Intervallo 1D:
$395.05
$401.47
Intervallo di 1 settimana:
$391.51
$413.59
Portata 52W:
$205.87
$495.55
Alnylam Pharmaceuticals Inc Stock (ALNY) Company Profile
Nome
Alnylam Pharmaceuticals Inc
Settore
Industria
Telefono
(617) 551-8200
Indirizzo
675 WEST KENDALL STREET, CAMBRIDGE, MA
Confronta ALNY con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
ALNY
Alnylam Pharmaceuticals Inc
|
400.69 | 52.67B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
VRTX
Vertex Pharmaceuticals Inc
|
462.99 | 116.51B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
783.71 | 82.52B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
849.95 | 52.08B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
177.42 | 37.70B | 447.02M | -1.18B | -906.14M | -6.1812 |
Alnylam Pharmaceuticals Inc Stock (ALNY) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-08-04 | Aggiornamento | Oppenheimer | Perform → Outperform |
| 2025-08-04 | Aggiornamento | Wolfe Research | Underperform → Peer Perform |
| 2025-07-30 | Ripresa | Raymond James | Outperform |
| 2025-07-21 | Iniziato | Truist | Buy |
| 2025-03-31 | Iniziato | Redburn Atlantic | Buy |
| 2025-03-24 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2024-11-12 | Downgrade | Wolfe Research | Peer Perform → Underperform |
| 2024-10-16 | Iniziato | Scotiabank | Sector Outperform |
| 2024-08-16 | Aggiornamento | Goldman | Neutral → Buy |
| 2024-02-16 | Downgrade | Goldman | Buy → Neutral |
| 2024-02-15 | Iniziato | Wolfe Research | Peer Perform |
| 2023-12-08 | Iniziato | Wells Fargo | Equal Weight |
| 2023-10-11 | Downgrade | Oppenheimer | Outperform → Perform |
| 2023-09-29 | Iniziato | Raymond James | Outperform |
| 2023-05-05 | Aggiornamento | BMO Capital Markets | Market Perform → Outperform |
| 2023-04-26 | Iniziato | SMBC Nikko | Neutral |
| 2023-03-21 | Iniziato | Bernstein | Outperform |
| 2023-01-18 | Iniziato | Canaccord Genuity | Buy |
| 2022-09-09 | Ripresa | Morgan Stanley | Equal-Weight |
| 2022-07-13 | Iniziato | Cantor Fitzgerald | Neutral |
| 2022-06-27 | Downgrade | Guggenheim | Buy → Neutral |
| 2022-06-07 | Iniziato | William Blair | Outperform |
| 2022-04-25 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2022-03-01 | Iniziato | Citigroup | Buy |
| 2022-02-03 | Aggiornamento | Guggenheim | Neutral → Buy |
| 2022-01-03 | Aggiornamento | Piper Sandler | Neutral → Overweight |
| 2021-11-22 | Aggiornamento | Goldman | Neutral → Buy |
| 2021-11-22 | Aggiornamento | RBC Capital Mkts | Sector Perform → Outperform |
| 2021-11-01 | Aggiornamento | Oppenheimer | Perform → Outperform |
| 2021-10-04 | Aggiornamento | UBS | Neutral → Buy |
| 2021-08-04 | Downgrade | Piper Sandler | Overweight → Neutral |
| 2021-02-22 | Downgrade | Guggenheim | Buy → Neutral |
| 2021-02-12 | Downgrade | Citigroup | Buy → Neutral |
| 2021-02-12 | Reiterato | H.C. Wainwright | Buy |
| 2021-01-25 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| 2020-09-30 | Ripresa | Berenberg | Hold |
| 2020-09-08 | Iniziato | Citigroup | Buy |
| 2020-08-11 | Downgrade | Oppenheimer | Outperform → Perform |
| 2020-05-13 | Iniziato | RBC Capital Mkts | Sector Perform |
| 2020-05-07 | Downgrade | JP Morgan | Overweight → Neutral |
| 2020-04-24 | Ripresa | Evercore ISI | Outperform |
| 2020-03-19 | Iniziato | Berenberg | Buy |
| 2019-12-19 | Reiterato | Chardan Capital Markets | Buy |
| 2019-11-20 | Iniziato | Oppenheimer | Outperform |
| 2019-11-13 | Iniziato | BofA/Merrill | Buy |
| 2019-05-23 | Ripresa | Goldman | Neutral |
| 2019-04-12 | Iniziato | Evercore ISI | Outperform |
| 2019-03-06 | Aggiornamento | Evercore ISI | In-line → Outperform |
| 2019-03-05 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2019-01-23 | Iniziato | UBS | Neutral |
| 2018-10-01 | Iniziato | Cantor Fitzgerald | Overweight |
| 2018-08-13 | Reiterato | Stifel | Buy |
| 2018-08-07 | Aggiornamento | Stifel | Hold → Buy |
| 2018-05-04 | Reiterato | Stifel | Hold |
| 2018-03-28 | Iniziato | Evercore ISI | In-line |
Mostra tutto
Alnylam Pharmaceuticals Inc Borsa (ALNY) Ultime notizie
Brighton Jones LLC Acquires 3,909 Shares of Alnylam Pharmaceuticals, Inc. $ALNY - MarketBeat
Alnylam Pharmaceuticals (ALNY) Valuation Check After NASDAQ-100 Entry and $250m Manufacturing Expansion - simplywall.st
Alnylam Pharmaceuticals (ALNY) Stock After Hours: Nasdaq-100 debut, fresh catalysts, and what to watch before Tuesday’s open (Dec. 23) - ts2.tech
Here’s why Alnylam Pharmaceuticals (ALNY) surged in Q3 - MSN
Alnylam Pharmaceuticals (ALNY) Stock on Dec. 22, 2025: Nasdaq-100 Debut, AMVUTTRA Momentum, Analyst Price Targets and the 2026 Outlook - ts2.tech
Alnylam Pharmaceuticals, Inc.(NasdaqGS: ALNY) added to NASDAQ-100 Index - marketscreener.com
Alnylam Pharmaceuticals Earnings Notes - Trefis
RNAi (RNA Interference) Technology Market to Reach US$ 6.63 - openPR.com
Alnylam Pharmaceuticals (ALNY) Stock: Nasdaq-100 Entry, Amvuttra Momentum, Analyst Targets and Key Risks to Know Before the Dec. 22, 2025 Market Open - ts2.tech
Bear Alert: Why Alnylam Pharmaceuticals Inc. stock could be next big winnerQuarterly Risk Review & Low Risk Profit Maximizing Plans - Улправда
118,800 Shares in Alnylam Pharmaceuticals, Inc. $ALNY Purchased by Congress Asset Management Co. - MarketBeat
Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Receives Average Recommendation of "Moderate Buy" from Brokerages - MarketBeat
PeptiDream (TSE:4587): Assessing Valuation After New IL-17 Oral Candidate and Alnylam siRNA Milestone - Yahoo Finance
Market Moves: Can Alnylam Pharmaceuticals Inc. stock beat market expectations this quarterQuarterly Profit Review & AI Driven Price Forecasts - ulpravda.ru
Alnylam Pharmaceuticals (ALNY) Stock News, Forecasts and Analyst Outlook on Dec. 20, 2025 - ts2.tech
Will Alnylam Pharmaceuticals Inc. stock remain a Wall Street favorite2025 Performance Recap & Expert Curated Trade Ideas - ulpravda.ru
Alnylam Pharmaceuticals, Inc. $ALNY Shares Sold by U.S. Capital Wealth Advisors LLC - MarketBeat
What PeptiDream (TSE:4587)'s New Oral IL-17 Program and RNAi Milestone Mean For Shareholders - Yahoo! Finance Canada
Is Alnylam Pharmaceuticals Inc. stock recession proofJuly 2025 Trends & AI Powered Market Entry Ideas - Улправда
Alnylam Pharmaceuticals (ALNY) Stock After Hours: What Happened After the Dec. 19, 2025 Close — and What to Watch Before the Next Market Open - ts2.tech
Portfolio Recap: Will Alnylam Pharmaceuticals Inc. stock remain a Wall Street favoriteJuly 2025 Trends & Accurate Entry and Exit Point Alerts - ulpravda.ru
Why Alnylam Pharmaceuticals Inc. stock remains undervaluedJuly 2025 Weekly Recap & Long-Term Safe Investment Ideas - Улправда
Can Alnylam Pharmaceuticals Inc. stock beat market expectations this quarterChart Signals & Free Long-Term Investment Growth Plans - Улправда
Here's Why Alnylam Pharmaceuticals (ALNY) Surged in Q3 - Finviz
Is Alnylam Pharmaceuticals Inc. (DUL) stock attractive post correctionMarket Activity Report & Weekly Stock Breakout Alerts - DonanımHaber
Will Alnylam Pharmaceuticals Inc. stock attract more institutional investorsOil Prices & Verified Momentum Stock Watchlist - DonanımHaber
How buybacks impact Alnylam Pharmaceuticals Inc. stock valueJuly 2025 Outlook & Fast Gaining Stock Strategy Reports - DonanımHaber
Here’s Why Alnylam Pharmaceuticals (ALNY) Surged in Q3 - Insider Monkey
Alnylam Pharmaceuticals, Inc. $ALNY Shares Acquired by Assenagon Asset Management S.A. - MarketBeat
Alnylam’s Manufacturing Expansion and Extra-Hepatic RNAi Delivery Could Be A Game Changer For Alnylam Pharmaceuticals (ALNY) - Yahoo Finance
Is It Too Late to Consider Alnylam After a 67.8% Surge in 2025? - Yahoo Finance
Demand prompts Alnylam’s $250 million manufacturing expansion - The Pharma Letter
PeptiDream and Alnylam Announce Achievement of Key Milestone in siRNA Conjugate Discovery Collaboration Demonstrating Peptide-Ligand Mediated Targeted siRNA Delivery to Specific Extrahepatic Tissues - BioSpace
Alnylam plans $250m investment in Norton manufacturing facility, US - Yahoo Finance
Alnylam to invest $250 million in expanding RNA drug manufacturing By Investing.com - Investing.com Nigeria
Alnylam launching $250 million biomanufacturing expansion in Norton - The Boston Globe
Alnylam's $250M Norton facility upgrade aims to slash need for 20 plants down to 2 - The Business Journals
Alnylam to Invest $250M in U.S. Manufacturing Expansion for RNAi Therapeutics - citybiz
Alnylam (ALNY) Advances Norton Facility with $250M Investment - GuruFocus
Alnylam Pharmaceuticals to Invest $250 Million on Enzymatic Ligation Manufacturing Platform - marketscreener.com
Alnylam to invest $250 million to add enzymatic ligation platform - marketscreener.com
Alnylam to Invest $250 Million to Add Enzymatic Ligation Platform to U.S. Manufacturing Facility to Meet Growing Global Demand for RNAi Therapeutics - Business Wire
Sanders Morris Harris LLC Makes New Investment in Alnylam Pharmaceuticals, Inc. $ALNY - MarketBeat
Alnylam Announces Health Canada Approval of AMVUTTRA® (vutrisiran), the First and Only RNAi Therapeutic for the Treatment of Cardiomyopathy in Adult Patients with ATTR Amyloidosis - BioSpace
Lululemon, Biogen to exit Nasdaq 100 with Alnylam, Seagate among additions - MSN
Analysts Conflicted on These Healthcare Names: Alnylam Pharma (ALNY), Novan (NOVN) and Dyadic International (DYAI) - The Globe and Mail
Alnylam announces Health Canada approval of Amvuttra® - marketscreener.com
Alnylam Pharmaceuticals (ALNY) Stock Price, Quote, News & History - Benzinga
Gene Therapy Market to Reach US$ 35.91 Billion by 2033 at 23.1% - openPR.com
Is Alnylam Entering A Corrective Phase After A Strong Run? - Sahm
Assessing Alnylam Pharmaceuticals’ (ALNY) Valuation After Its Inclusion in the Nasdaq 100 Index - Yahoo Finance
Alnylam Pharmaceuticals Inc Azioni (ALNY) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Alnylam Pharmaceuticals Inc Azioni (ALNY) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Fitzgerald Kevin Joseph | CSO & EVP, Head of Research |
Nov 17 '25 |
Option Exercise |
119.13 |
8,161 |
972,220 |
33,392 |
| Fitzgerald Kevin Joseph | CSO & EVP, Head of Research |
Nov 17 '25 |
Sale |
452.18 |
12,128 |
5,483,990 |
21,264 |
0.47%
0.19%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):